See more : MPLX LP (MPLXP) Income Statement Analysis – Financial Results
Complete financial analysis of Nektar Therapeutics (NKTR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nektar Therapeutics, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lion One Metals Limited (LOMLF) Income Statement Analysis – Financial Results
- Nxera Pharma Co., Ltd. (4565.T) Income Statement Analysis – Financial Results
- Atlas Copco AB (ATLFF) Income Statement Analysis – Financial Results
- Allergy Therapeutics plc (AGY.L) Income Statement Analysis – Financial Results
- Ackroo Inc. (AKR.V) Income Statement Analysis – Financial Results
Nektar Therapeutics (NKTR)
About Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.12M | 92.06M | 101.91M | 152.92M | 114.62M | 1.19B | 307.71M | 165.44M | 230.78M | 200.71M | 148.92M | 81.19M | 71.48M | 159.04M | 71.93M | 90.19M | 273.03M | 217.72M | 126.28M | 114.27M | 106.26M | 94.85M | 77.47M | 51.63M | 41.36M | 21.80M | 16.25M | 6.90M | 3.40M | 1.70M |
| Cost of Revenue | 36.64M | 21.64M | 24.90M | 19.48M | 21.37M | 24.41M | 30.55M | 30.22M | 34.10M | 28.53M | 38.51M | 30.43M | 21.89M | 25.67M | 30.95M | 35.04M | 147.52M | 118.09M | 36.00M | 19.80M | 14.68M | 7.02M | 4.17M | 0.00 | 0.00 | 0.00 | 0.00 | -1.20M | -1.10M | -500.00K |
| Gross Profit | 53.48M | 70.42M | 77.01M | 133.44M | 93.24M | 1.17B | 277.16M | 135.22M | 196.68M | 172.17M | 110.41M | 50.76M | 49.59M | 133.37M | 40.98M | 55.15M | 125.51M | 99.63M | 90.28M | 94.47M | 91.58M | 87.83M | 73.30M | 51.63M | 41.36M | 21.80M | 16.25M | 8.10M | 4.50M | 2.20M |
| Gross Profit Ratio | 59.34% | 76.50% | 75.57% | 87.26% | 81.35% | 97.95% | 90.07% | 81.74% | 85.22% | 85.78% | 74.14% | 62.52% | 69.37% | 83.86% | 56.98% | 61.15% | 45.97% | 45.76% | 71.49% | 82.67% | 86.19% | 92.60% | 94.62% | 100.00% | 100.00% | 100.00% | 100.00% | 117.39% | 132.35% | 129.41% |
| Research & Development | 114.16M | 218.32M | 400.27M | 408.68M | 434.57M | 399.54M | 268.46M | 203.80M | 182.79M | 147.73M | 190.01M | 148.68M | 126.77M | 108.07M | 95.11M | 154.42M | 153.58M | 149.38M | 151.66M | 133.52M | 131.53M | 157.38M | 139.65M | 101.54M | 64.08M | 35.40M | 23.65M | 14.40M | 9.00M | 0.00 |
| General & Administrative | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 77.42M | 92.33M | 122.84M | 104.68M | 98.71M | 81.44M | 52.36M | 44.28M | 43.27M | 40.93M | 40.53M | 41.61M | 46.76M | 40.99M | 41.01M | 51.50M | 56.34M | 78.32M | 43.85M | 30.97M | 22.02M | 26.02M | 18.86M | 13.93M | 7.87M | 8.39M | 6.33M | 4.00M | 3.20M | 7.40M |
| Other Expenses | 0.00 | -116.00K | -24.41M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 392.00K | 983.00K | 0.00 | 0.00 | 0.00 | -68.11M | -48.25M | 31.16M | 69.55M | 3.92M | 4.22M | 4.51M | 25.49M | 0.00 | 0.00 | 0.00 | 0.00 | 1.20M | 4.30M | 7.90M |
| Operating Expenses | 190.90M | 310.66M | 523.11M | 513.36M | 533.28M | 480.98M | 320.83M | 248.08M | 226.05M | 188.66M | 230.54M | 190.29M | 173.53M | 149.05M | 136.12M | 137.80M | 161.66M | 258.86M | 265.06M | 168.41M | 157.76M | 187.91M | 184.00M | 115.48M | 71.95M | 43.79M | 29.97M | 19.60M | 13.30M | 7.90M |
| Cost & Expenses | 227.55M | 332.29M | 548.01M | 532.84M | 554.65M | 505.39M | 351.37M | 278.29M | 260.16M | 217.19M | 269.05M | 220.72M | 195.42M | 174.72M | 167.06M | 172.84M | 309.18M | 376.95M | 301.05M | 188.21M | 172.44M | 194.93M | 188.17M | 115.48M | 71.95M | 43.79M | 29.97M | 18.40M | 12.20M | 7.40M |
| Interest Income | 19.01M | 6.67M | 2.57M | 18.28M | 46.34M | 37.57M | 4.52M | 2.39M | 1.68M | 814.00K | 732.00K | 2.32M | 2.24M | 1.55M | 3.69M | 12.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.33M | 28.91M | 47.31M | 37.12M | 46.35M | 42.78M | 40.95M | 42.18M | 38.90M | 38.76M | 40.76M | 33.55M | 10.22M | 11.17M | 12.18M | 15.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.82M | 12.20M | 13.00M | 12.50M | 11.00M | 8.80M | 12.60M | 13.20M | 12.86M | 12.93M | 14.28M | 14.51M | 14.95M | 16.55M | 14.88M | 22.49M | 28.15M | 32.64M | 26.23M | 19.19M | 18.42M | 18.97M | 40.39M | 10.12M | 7.25M | 3.60M | 2.44M | 1.20M | 1.10M | 500.00K |
| EBITDA | -243.11M | -323.87M | -462.97M | -394.33M | -382.70M | 734.30M | -42.52M | -97.27M | -29.37M | -2.74M | -106.01M | -124.10M | -107.79M | -9.33M | -75.72M | 2.54M | -7.12M | -125.72M | -147.07M | -54.76M | -47.77M | -81.11M | -70.32M | -53.72M | -23.34M | -18.39M | -11.29M | -10.30M | -7.70M | -5.20M |
| EBITDA Ratio | -269.75% | -239.57% | -445.31% | -227.22% | -332.01% | 61.71% | -7.93% | -57.49% | -6.43% | -1.37% | -70.33% | -149.92% | -149.33% | 1.52% | -106.44% | -197.91% | -21.36% | -46.66% | -58.44% | -40.07% | -75.27% | -84.47% | 103.45% | -22.74% | -32.52% | -84.39% | -69.46% | -172.46% | -264.71% | -341.18% |
| Operating Income | -137.43M | -240.24M | -446.10M | -379.92M | -440.04M | 687.93M | -59.64M | -112.86M | -29.37M | -16.49M | -120.13M | -141.20M | -123.94M | -28.26M | -95.13M | -82.65M | -36.15M | -159.23M | -182.63M | -73.94M | -66.19M | -100.08M | -256.96M | -66.14M | -40.48M | -21.99M | -13.72M | -11.50M | -8.80M | -5.70M |
| Operating Income Ratio | -152.49% | -260.97% | -437.76% | -248.45% | -383.92% | 57.65% | -19.38% | -68.22% | -12.73% | -8.21% | -80.67% | -173.91% | -173.39% | -17.77% | -132.25% | -91.65% | -13.24% | -73.14% | -144.63% | -64.71% | -62.29% | -105.52% | -331.70% | -128.10% | -97.89% | -100.89% | -84.46% | -166.67% | -258.82% | -335.29% |
| Total Other Income/Expenses | -138.83M | -124.75M | -77.18M | -64.03M | -19.00K | -5.21M | -36.43M | -39.79M | -51.30M | -37.94M | -39.64M | -30.25M | -9.02M | -8.80M | -7.64M | 47.51M | 4.70M | 5.30M | -2.62M | -28.11M | 19.67M | -7.39M | 6.96M | -31.26M | -9.89M | 0.00 | 0.00 | 1.60M | 1.30M | 600.00K |
| Income Before Tax | -276.26M | -364.98M | -523.28M | -443.95M | -440.05M | 682.73M | -96.08M | -152.65M | -80.67M | -54.43M | -159.77M | -171.45M | -132.96M | -37.06M | -102.77M | 35.14M | -31.45M | -153.93M | -185.25M | -102.05M | -46.51M | -107.47M | -250.01M | -97.40M | -50.37M | 0.00 | 0.00 | -9.90M | -7.50M | -5.10M |
| Income Before Tax Ratio | -306.54% | -396.48% | -513.49% | -290.32% | -383.93% | 57.21% | -31.22% | -92.27% | -34.96% | -27.12% | -107.28% | -211.17% | -186.01% | -23.30% | -142.88% | 38.97% | -11.52% | -70.70% | -146.70% | -89.31% | -43.77% | -113.31% | -322.72% | -188.66% | -121.80% | 0.00% | 0.00% | -143.48% | -220.59% | -300.00% |
| Income Tax Expense | -200.00K | 3.22M | 557.00K | 493.00K | 613.00K | 1.41M | 616.00K | 876.00K | 506.00K | -512.00K | 2.25M | 406.00K | 1.02M | 881.00K | -253.00K | -806.00K | 1.31M | 828.00K | -137.00K | -163.00K | 169.00K | 7.39M | 139.31M | 33.56M | 7.85M | -3.63M | -3.74M | -1.50M | -1.10M | -400.00K |
| Net Income | -276.06M | -368.20M | -523.84M | -444.44M | -440.67M | 681.31M | -96.69M | -153.52M | -81.18M | -53.92M | -162.01M | -171.86M | -133.98M | -37.94M | -102.52M | -34.34M | -32.76M | -154.76M | -185.11M | -101.89M | -46.68M | -107.47M | -250.01M | -97.40M | -38.45M | -18.36M | -9.98M | -10.00M | -7.70M | -5.30M |
| Net Income Ratio | -306.31% | -399.98% | -514.03% | -290.65% | -384.47% | 57.09% | -31.42% | -92.80% | -35.17% | -26.86% | -108.79% | -211.67% | -187.43% | -23.85% | -142.52% | -38.07% | -12.00% | -71.08% | -146.59% | -89.16% | -43.93% | -113.31% | -322.72% | -188.66% | -92.96% | -84.22% | -61.44% | -144.93% | -226.47% | -311.76% |
| EPS | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| EPS Diluted | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 | 3.78 | -0.62 | -1.10 | -0.61 | -0.42 | -1.40 | -1.50 | -1.19 | -0.40 | -1.11 | -0.37 | -0.36 | -1.72 | -2.15 | -1.30 | -0.84 | -1.94 | -4.71 | -2.32 | -1.13 | -0.58 | -0.36 | -0.44 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.57M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
| Weighted Avg Shares Out (Dil) | 190.00M | 187.14M | 183.30M | 178.58M | 174.99M | 180.12M | 155.95M | 139.60M | 132.46M | 126.87M | 115.73M | 114.82M | 112.94M | 94.08M | 92.77M | 92.41M | 91.88M | 89.79M | 85.92M | 78.46M | 55.82M | 55.28M | 53.14M | 42.00M | 34.02M | 31.44M | 27.58M | 22.73M | 19.74M | 12.33M |
Nektar Therapeutics (NKTR) Q2 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2023 Earnings Conference Call August 8, 2023 5:00 PM ET Company Participants Vivian Wu - Director, Investor Relations and Corporate Affairs Howard Robin - President and CEO Dr. Jonathan Zalevsky - Chief, Research and Development...
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
SAN FRANCISCO , Aug. 8, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2023. Cash and investments in marketable securities at June 30, 2023, were $409.4 million as compared to...
Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment
Nektar Therapeutics on Monday sued Eli Lilly , accusing the drugmaker of undermining the prospects for Rezpeg, which Nektar was developing as a treatment for various autoimmune diseases.
Nektar rallies after releasing new data for rezpeg after Eli Lilly got it wrong
Nektar Therapeutics (NASDAQ:NKTR) shares rallied more than 15% in Monday pre-market trading after the company released new efficacy data from phase 1b studies from rezpegaldesleukin (rezpeg) after the data were previously incorrectly calculated by Eli Lilly. The new and corrected data...
Nektar Therapeutics' stock jumps premarket after it says data presented by Eli Lilly for a skin treatment was incorrectly calculated
Nektar Therapeutics' stock NKTR, +3.14% jumped 12.7% in premarket trade Monday, after the company said that efficacy data previously generated by its former partner Eli Lilly & Co. LLY, +0.07% for its atopic dermatitis treatment rezpegaldesleukin and presented at the...
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
EASI-Related and PASI-Related Clinical Efficacy Endpoints in Atopic Dermatitis and Psoriasis Studies Were Incorrectly Calculated by Lilly and Were Reported Erroneously at EADV 2022 SAN FRANCISCO , Aug. 7, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that efficacy...
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
SAN FRANCISCO , Aug. 1, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2023 on Tuesday, August 8, 2023, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive...
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
SAN FRANCISCO , June 12, 2023 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 1:20...
Nektar Therapeutics (NKTR) Q1 2023 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q1 2023 Earnings Conference Call May 9, 2023 5:00 PM ET Company Participants Vivian Wu - Investor Relations Howard Robin - President and Chief Executive Officer Jonathan Zalevsky - Chief, Research and Development Mary Tagliaferri -...
Forget Bargain Hunting, Buy 5 Stocks With Rising P/E
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Disney (DIS), Casey's General Stores (CASY), OpGen (OPGN), Accelerate Diagnostics (AXDX) and Nektar Therapeutics (NKTR).
Source: https://incomestatements.info
Category: Stock Reports